Recombinant Human NT-proBNP Protein (N-6His-Flag)

Name: Recombinant Human NT-proBNP Protein (N-6His-Flag)
Brand: Beta LifeScience
SKU: BL-1923NP
Availability: InStock

BL-1923NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Brain-type Natriuretic Peptide is produced by our E.coli expression system and the target gene encoding His27-Arg102 is expressed with a 6His, Flag tag at the N-terminus.
Accession	P16860
Synonym	Natriuretic peptides B; Gamma-brain natriuretic peptide; NPPB; BNP
Gene Background	Brain-type Natriuretic Peptide (BNP) is a nonglycosylated peptide that is produced predominantly by ventricular myocytes and belongs to the natriuretic peptide family. Proteolytic cleavage of the 12 kDa BNP precursor gives rise to N-terminal Pro BNP (NT-proBNP) and mature BNP. N-terminal proB-type natriuretic peptide (NT-proBNP), a useful marker of heart failure (HF), is considered to be secreted mainly from the ventricle, increased serum NT-proBNP levels are also encountered in conditions such as atrial fibrillation (AF) and atrial septal defect in patients without HF.
Molecular Mass	11 KDa
Apmol Mass	14 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Cardiac hormone that plays a key role in mediating cardio-renal homeostasis. May also function as a paracrine antifibrotic factor in the heart. Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins that drive various biological responses. Involved in regulating the extracellular fluid volume and maintaining the fluid-electrolyte balance through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Binds the clearance receptor NPR3.; May affect cardio-renal homeostasis. Able to promote the production of cGMP although its potency is very low compared to brain natriuretic peptide 32.; May have a role in cardio-renal homeostasis. Able to promote the production of cGMP.
Subcellular Location	[NT-proBNP]: Secreted.; [proBNP(3-108)]: Secreted.; [Brain natriuretic peptide 32]: Secreted.; [BNP(3-32)]: Secreted.
Protein Families	Natriuretic peptide family
Database References	HGNC: 7940 OMIM: 600295 KEGG: hsa:4879 STRING: 9606.ENSP00000365651 UniGene: PMID: 29327361 Combinative index (arterial lactate, NT-proBNP and CRP) could serve as a valuable predictor for the 28-day mortality rate in patients with sepsis. PMID: 30158031 Patients diagnosed with portopulmonary hypertension (POPH) had significantly higher BNP levels in comparison with those patients without. In contrast, PELD/MELD scores showed an almost negligible correlation with the BNP level. Liver transplantation was successful in 3 asymptomatic biliary atresia patients with POPH who had high BNP levels despite the low PELD/MELD scores. PMID: 29733490 NT-proBNP was associated with poor outcomes for patients with acute respiratory distress syndrome, and its level predicted mortality. PMID: 28322314 Levels of N-terminal pro-brain-type natriuretic peptide increases in response to exercise in patients with pulmonary arterial hypertension. PMID: 29334941 Admission NT-proBNP is an independent predictor for short- and long-term adverse events in Takotsubo syndrome patients. PMID: 29675571 Report a weak correlation between B-type natriuretic peptide and within-visit blood pressure variability. PMID: 29604077 Lung ultrasound, serum B-type natriuretic peptide levels, and echocardiography can be used for outcome prediction in patients with acute heart failure. PMID: 29532155 Data suggest that intact FGF23 level in plasma is independent predictor of cardiovascular death in patients with heart failure and provides added value to standard of care, natriuretic peptide (NT-proBNP) plasma level, for risk estimation. This study was conducted in Belgium. (FGF23 = fibroblast growth factor 23; NT-proBNP = aminoterminal pro-B-type natriuretic peptide) PMID: 30205090 Report decreased NT-proBNP levels in heart failure patients in contemporary heart failure management programs. PMID: 29656687 NT-proBNP may have a role in myocardial conduction abnormalities in patients with diabetes mellitus PMID: 29121498 recombinant human brain natriuretic peptide can regulate expression of IL-6, TNF-alpha, and IL-10 in lipopolysaccharide-activated RAW 264.7 cells. PMID: 29754152 n elderly patients with symptoms of heart failure ST2 was not superior to NTproBNP to predict all cause or cardiovascular mortality. Furthermore, it is unclear if the combination of ST2 and NTproBNP will improve long-term prognostication beyond what is achieved by NTproBNP alone. PMID: 29355441 current cutoffs for diagnosing HF for NT-proBNP and BNP have relatively low diagnostic concordance and correlation, particularly among patients with chronic kidney disease PMID: 30111510 Elevated plasma NT-proBNP and KIM-1 in patients with stage 5 chronic kidney disease (CKD5) undergoing maintenance hemodialysis (HD) and HF (+) (heart failure)CKD5-HD patients suggest that natriuretic peptides and KIM-1 may contribute to the pathogenesis of HF in CKD5-HD patients. PMID: 28990414 Increased levels of NT-proBNP seems to be a better biomarker of multidrug antihypertensive therapy requirement than CT-proAVP. PMID: 29190613 Baseline NT-proBNP concentration was associated with short-term stroke among patients hospitalized with acute heart filure. Stroke risk assessment models should consider incorporation of NT-proBNP measurement. PMID: 28905172 Suggest potential role for BNP as a protective endogenous factor against cerebral ischemia. PMID: 29203579 In children with chronic kidney disease, BNP is an indicator of heart failure correlating with renal function parameters and left ventricular mass index. PMID: 29775443 Data indicate that B-type natriuretic peptide (BNP) was outcome associated in acute heart failure patients. PMID: 28132515 Combination of coronary artery calcium score and NT-proBNP could be used to identify a group of coronary artery disease patients where MPI could be averted with a high degree of diagnostic safety. PMID: 27005324 NT-pro-BNP was not significantly different between subjects with 1-2 stenotic coronary arteries compared to those with 3 stenotic coronary arteries. PMID: 28845719 Serum levels of ST2, IL-33 and BNP were independent risk factors for major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. PMID: 28623858 Circulating NT-proBNP levels are lower in overweight patients, even in those with diabetes, compared to controls. PMID: 28946871 Report usefulness of point-of-care test for NT-proBNP in primary care for the diagnosis of heart failure. PMID: 29263170 In-hospital mortality in patients with sepsis and low risk of sepsis-related organ failure was associated with NT-proBNP > 1,330 pg/ml. PMID: 28473224 The results of the present study suggest the possible use of the molecular pathology of BNP for the determination of the terminal cardiac function in SCD and analysis of its death mechanism in forensic practice. PMID: 28765973 In patients with a recent acute coronary syndrome and type 2 diabetes mellitus, BNP and NT-proBNP were powerful predictors of cardiovascular outcomes beyond heart failure and death, ie, were also predictive of MI and stroke. PMID: 28554908 Data suggest that subjects with morbid obesity exhibit down-regulation of serum levels of BNP compared to control subjects. This study was conducted in Italy. PMID: 27426417 Increased baseline values of BNP (and BigET-1) after acute myocardial infarction, were independently predictive of future cardiovascular events. PMID: 28284500 Patients with acute exacerbation of COPD and elevated NT-pro-BNP levels had increased hospital length of stay and need for intensive care. PMID: 28458528 BNP blood level is a biomarker for the the severity of hand-foot-mouth disease PMID: 28962547 Plasma levels of NT-pro-BNP were significantly higher in hypertrophic cardiomyopathy (HCM) patients with more advanced disease. Elevated NT-pro-BNP not only reflects the diastolic impairment of the LV, but it might also be the result of cardiac ischemia in patients with HCM. PMID: 28336204 Increased preoperative brain natriuretic peptide concentration was associated with risk of serious adverse events in pediatric cardiac surgery patients. PMID: 27919715 NPPB SNPs were not associated with insulin resistance in older adults. PMID: 27101535 Higher blood levels of NT-proBNP was associated with incident cognitive impairments. PMID: 27567834 In people with Type 2 diabetes, high baseline B-type natriuretic peptide levels were significantly associated with future atrial fibrillation development. PMID: 26173591 Plasma BNP levels were independently associated with functional outcomes 3 months after stroke onset in atrial fibrillation patients. PMID: 28253498 Short-term follow-up BNP and percent change in BNP level are significant prognostic factors of all-cause mortality in hospitalized heart failure patients. PMID: 28774268 NT-proBNP showed an incremental prognostic value for prediction of adverse outcomes when added to the clinical and echocardiographic parameters in patients with left ventricular dysfunction. PMID: 28349264 BNP gene body hypermethylation is associated with the risk of rheumatic heart disease (RHD), and also influenced by the warfarin anticoagulant therapy of RHD patients after surgery, which could represent novel and promising targets for therapeutic development. PMID: 27920275 IL-6 receptor blockade has an effect on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis PMID: 27744141 An exercise-associated increase in hs-cTnT and NT-proBNP occurred in response to a 60-minute maximal swimming test that was independent of pubertal status/adolescent vs adults. The present data also suggests that baseline and postexercise hs-cTnT values are higher in male compared with female, with no sex differences in NT-proBNP values. PMID: 29173327 An increase in NT-proBNP is a strong predictor of outcome in patients with left ventricular non-compaction cardiomyopathy. PMID: 28268080 Brain Natriuretic Peptide levels increased as heart failure duration increased. PMID: 28268084 In this hospitalized heart failure cohort, atrial fibrillation/flutter status did not influence post-discharge NT-proBNP trajectory. PMID: 27748006 NT-proBNP and BNP levels were statistically higher in patients with heart failure and anemia compared to patients with heart failure and without anemia. PMID: 28587950 The rs198389 G allele in the NPPB promoter is associated with elevated levels of NT-proBNP throughout adult life, reduced blood pressure, hypertension and cardiovascular mortality, and increased lifespan. PMID: 28341776 Atrial fibrillation risk discrimination was not significantly improved by the addition of NT-proBNP levels to the Framingham AF risk model. PMID: 27194537 Combination of high serum BNP levels, along with high soluble AXL had greater predictive value for heart failure than BNP alone. PMID: 27718443

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.